{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-062859","form_type":"8-K","ticker":"GRML","cik":"0001907223","company_name":"Greenland Mines Ltd","filed_at":"2025-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.568879+00:00","generated_at":"2026-05-18T08:47:35.769509+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA grants Orphan Drug Designation for Klotho's KLTO-202 to treat ALS","bullets":["FDA granted Orphan Drug Designation for KLTO-202 (s-KL-AAV.myo) for ALS.","Designation provides tax credits for clinical trials, GDUFA fee waiver, and 7-year U.S. market exclusivity.","Company completed proof-of-concept in two animal ALS models; initiating manufacturing and FDA/EMA meetings.","KLTO-202 is a gene therapy using a muscle-specific desmin promoter to deliver secreted-Klotho protein."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-062859","json":"https://secwatch.observer/filing/0001213900-25-062859.json","markdown":"https://secwatch.observer/filing/0001213900-25-062859.md","text":"https://secwatch.observer/filing/0001213900-25-062859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907223/000121390025062859/0001213900-25-062859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907223/000121390025062859/ea0248604-8k_klotho.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:47:35.769509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}